Skip to Content

Prolensa Approval History

FDA Approved: Yes (First approved April 5, 2013)
Brand name: Prolensa
Generic name: bromfenac
Dosage form: Ophthalmic Solution
Company: Bausch + Lomb
Treatment for: Postoperative Ocular Inflammation

Prolensa (bromfenac ophthalmic solution) is a topical nonsteroidal anti-inflammatory indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Development History and FDA Approval Process for Prolensa

DateArticle
Apr  8, 2013Approval Bausch + Lomb Receives FDA Approval for Prolensa

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide